Liporex

Simvastatin, the active ingredient in Liporex, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol levels and is used to reduce the risk of cardiovascular events in patients with hypercholesterolemia. GNH USA supplies Liporex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Simvastatin acts on the lipid metabolism pathway to manage cholesterol disorders and reduce cardiovascular risk.

Hypercholesterolemia: lowers total and LDL cholesterol levels. Heterozygous familial hypercholesterolemia: improves lipid profile in genetically predisposed patients. Prevention of cardiovascular events: reduces incidence of heart attack and stroke in at‑risk individuals.

Simvastatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Gastrointestinal upset: nausea, abdominal pain, or dyspepsia. - Myalgia: muscle aches without weakness. - Elevated liver enzymes: mild transaminase increases. - Dizziness: occasional light‑headedness. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of kidney injury. - Severe hepatic injury: marked elevation of liver enzymes or jaundice. - Myopathy: muscle weakness with elevated CK levels. - Allergic reactions: rash, pruritus, or angioedema. - Hepatotoxicity: hepatitis or liver failure. - Anaphylaxis: rare life‑threatening hypersensitivity.

Before initiating therapy and during treatment, certain precautions should be observed.

Assess liver function: obtain baseline hepatic enzyme tests. Monitor creatine kinase: check if muscle symptoms develop. Avoid use in active liver disease: contraindicated in patients with unexplained persistent elevations of transaminases. Use caution with grapefruit juice: it can increase simvastatin plasma concentrations. Review concomitant medications: assess for drugs that affect CYP3A4 metabolism. Store at ambient temperature: keep in the original pack, protect from moisture.

Simvastatin interacts with several medicines that can alter its plasma levels or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may cause dangerous increases in simvastatin exposure. - Gemfibrozil: significantly raises risk of myopathy and rhabdomyolysis. - High‑dose niacin: enhances muscle toxicity.

Moderate Interactions (Monitor Closely): - Amlodipine: may modestly increase simvastatin concentrations. - Warfarin: requires INR monitoring due to potential anticoagulant effect alteration.